Navigation Links
Hepatitis C treatment reduces the virus but serious liver problems may progress
Date:11/6/2007

Patients with chronic hepatitis C and advanced liver disease who did not respond to previous standard therapy experienced significant decreases in their liver enzymes, viral levels, and liver inflammation following treatment with long-term pegylated interferon. However, the treatment did not slow or prevent the progression of serious liver disease. These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) and were reported at the annual meeting of the American Association for the Study of Liver Disease in Boston on November 5, 2007. HALT-C is funded by the National Institutes of Health (NIH) with additional support from Hoffmann-La Roche Inc.

"The HALT-C trial unequivocally demonstrated that maintenance therapy with peginterferon does not prevent progression of liver disease among patients who have failed prior treatments," said James Everhart, M.D., project scientist for HALT-C and a program director for the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the principal sponsor of HALT-C at NIH. "These results add to the incentive to develop more effective drugs that will benefit patients with severe liver disease due to hepatitis C."

HALT-C, a randomized multicenter trial of 1,050 patients with chronic hepatitis C who had failed prior treatment to eradicate the infection, assessed whether long-term treatment with peginterferon alfa-2a reduced the development of cirrhosis, liver failure, or liver cancer. The 517 patients randomized to the treatment arm received 90 micrograms of peginterferon in weekly injections for 3.5 years. The 533 patients in the control arm underwent the same follow-up and care as the treated patients including liver biopsies, quarterly clinic visits, and blood tests. All patients had advanced liver fibrosis, a gradual scarring of the liver that puts patients at risk for progressive liver disease.

The outcomes assessed in HALT-C were death, liver cancer, ascites (excess fluid in the abdomen), or encephalopathy (brain and nervous system damage), and for those who did not have cirrhosis initially, the development of cirrhosis. At the end of the study, 34.1 percent of the patients in the treated group and 33.8 percent of the patients in the control group had experienced at least one outcome. Patients in the treated group had significantly lower blood levels of the hepatitis C virus and less liver inflammation. However, there was no major difference in rates of any of the primary outcomes between groups.

Among treated patients, 17 percent stopped peginterferon by one year and six months and 30 percent stopped the drug two years later. Adverse events such as infections, musculoskeletal or digestive problems were the most common reasons patients stopped taking the drug.

Viral hepatitis C infects more than 100 million persons worldwide and as many as 4 million persons in the United States. Hepatitis C ranks with alcohol abuse as the most common cause of chronic liver disease and leads to about 1,000 liver transplants in the United States each year. The best current antiviral therapy consists of pegylated interferon given by injection in combination with oral ribavirin prescribed for about 6 months to a year. This therapy eliminates the virus in about 50 percent of infected patients.


'/>"/>

Contact: Leslie Curtis
niddkmedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

Related medicine news :

1. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
2. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
3. Stanford researchers find way to fight treacherous hepatitis B
4. Medical Services International Agrees to Retail the VScan Hepatitis B&C Test Kits in SE Asia
5. Hepatitis A Vaccine Best Bet to Treat Virus
6. Hepatitis C Testing Recommended for Anyone with a Tattoo
7. Is it pancreatitis in acute abdominal pain in acute viral hepatitis?
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
10. Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
11. HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Alexandria, Virginia (PRWEB) , ... March 23, 2017 ... ... quality public health services to their communities, 16 more public health departments have ... This week’s decisions bring another 4.5 million people into the expanding network of ...
(Date:3/23/2017)... ... ... are unaware of the dangers that infectious bacteria play in mouth disease, while 1 out ... that dentists recommend. The ramifications of improper oral upkeep go far beyond bad breath and ... hours of work each year due to dental issues. That is why Mediaplanet is proud ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Los Angeles based healthcare technology company California Healthcom Group (CHG). , The ... and healthcare arena. With headquarters in California, CHG is a growing, internationally recognized ...
(Date:3/23/2017)... York City (PRWEB) , ... March 23, 2017 , ... ... last fall, FaceCradle , the most-funded travel pillow in crowdfunding history, ... speed delivery of its wildly popular travel innovation to Americans. , “We’re excited to ...
(Date:3/23/2017)... Los Angeles, CA (PRWEB) , ... March 23, 2017 , ... ... half of all Americans, yet poor sleep is likely not the only cause of ... these undesirable characteristics that make you look older or in poor health are likely ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017   BioSpace , ... resource, has partnered with Indiana Biosciences Research Institute ... organizations and educational institutions to bring the state,s ... first-ever BioIndiana Hotbed map, an artistic representation of the ... was presented to Vice President Mike Pence , ...
(Date:3/23/2017)... 23, 2017  Ethicon* today announced the completion ... privately held medical device company that manufactures and ... surgical treatment of Gastroesophageal Reflux Disease (GERD). This ... its portfolio of minimally invasive options for patients ... terms of the transaction have not been disclosed. ...
(Date:3/23/2017)... , March 23, 2017 CENTRO DE IMAGEM ... 157, paragraph 4 of Law 6,404/76 and Instruction 358/02 ... informs its shareholders and the market in general that ... subsidiary Centro de Diagnosticos por Imagem Ltda. (" CDI ... interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " and ...
Breaking Medicine Technology: